Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

GSK 3745417

Next Previous
Drug Profile

GSK 3745417

Alternative Names: GSK-3745417

Latest Information Update: 10 Oct 2024

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator GlaxoSmithKline
  • Developer GSK
  • Class Antineoplastics
  • Mechanism of Action STING1 protein stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Acute myeloid leukaemia; Myelodysplastic syndromes; Solid tumours

Most Recent Events

  • 10 Oct 2024 Phase-I development in Solid-tumours (Combination therapy, Late-stage disease, Recurrent, Second-line therapy or greater) in France, Spain, Netherlands, South Korea, Australia, Canada, USA is still ongoing (NCT03843359)
  • 10 Oct 2024 Phase-I development in Solid-tumours (Late-stage disease, Monotherapy, Recurrent, Second-line therapy or greater) in France, Spain, Netherlands, South Korea, Australia, Canada, USA is still ongoing (NCT03843359)
  • 28 Apr 2024 No recent reports of development identified for phase-I development in Solid-tumours(Combination therapy, Late-stage disease, Recurrent, Second-line therapy or greater) in Australia (IV, Injection)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top